(NASDAQ: PGEN) Precigen's forecast annual revenue growth rate of 198.74% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.34%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.3%.
Precigen's revenue in 2024 is $6,225,000.On average, 2 Wall Street analysts forecast PGEN's revenue for 2024 to be $1,534,586,227, with the lowest PGEN revenue forecast at $1,493,514,576, and the highest PGEN revenue forecast at $1,575,657,878. On average, 3 Wall Street analysts forecast PGEN's revenue for 2025 to be $10,073,755,815, with the lowest PGEN revenue forecast at $1,620,463,315, and the highest PGEN revenue forecast at $26,111,613,170.
In 2026, PGEN is forecast to generate $53,691,849,007 in revenue, with the lowest revenue forecast at $53,691,849,007 and the highest revenue forecast at $53,691,849,007.